People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| EpiBone, Inc. | — | Other | Series B | $47.8M | $19.9M | 2022 |
| Omnipulse Biosciences, Inc. | — | Biotechnology | Series A | $7.0M | $47.8M | 2023 |
David Zhu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Zhu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 2 | 36 |
| Joseph DeSimone | 1 | 5 |
| Elma Hawkins | 1 | 2 |
| Gordana Vunjak-Novakovic | 1 | 2 |
| Robert Farra | 1 | 1 |
| Felicia Hsu | 1 | 1 |
| Nina Tandon | 1 | 1 |
| Sarindr Bhumiratana | 1 | 1 |
| Ana Jacklenec | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.